table of content
1 Introduction to Research & Analysis Reports
1.1 PD-1 and PD-L1 Immunotherapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global PD-1 and PD-L1 Immunotherapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global PD-1 and PD-L1 Immunotherapy Overall Market Size
2.1 Global PD-1 and PD-L1 Immunotherapy Market Size: 2022 VS 2030
2.2 Global PD-1 and PD-L1 Immunotherapy Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top PD-1 and PD-L1 Immunotherapy Players in Global Market
3.2 Top Global PD-1 and PD-L1 Immunotherapy Companies Ranked by Revenue
3.3 Global PD-1 and PD-L1 Immunotherapy Revenue by Companies
3.4 Top 3 and Top 5 PD-1 and PD-L1 Immunotherapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies PD-1 and PD-L1 Immunotherapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Players in Global Market
3.6.1 List of Global Tier 1 PD-1 and PD-L1 Immunotherapy Companies
3.6.2 List of Global Tier 2 and Tier 3 PD-1 and PD-L1 Immunotherapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global PD-1 and PD-L1 Immunotherapy Market Size Markets, 2022 & 2030
4.1.2 PD-1 inhibitor
4.1.3 PD-L1 inhibitor
4.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
4.2.1 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
4.2.2 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
4.2.3 By Type - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global PD-1 and PD-L1 Immunotherapy Market Size, 2022 & 2030
5.1.2 Solid Tumors
5.1.3 Blood-related Tumors
5.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
5.2.1 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
5.2.2 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
5.2.3 By Application - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global PD-1 and PD-L1 Immunotherapy Market Size, 2022 & 2030
6.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue & Forecasts
6.2.1 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2018-2023
6.2.2 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue, 2024-2030
6.2.3 By Region - Global PD-1 and PD-L1 Immunotherapy Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.3.2 US PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.4.2 Germany PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.3 France PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.4 U.K. PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.5 Italy PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.6 Russia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.7 Nordic Countries PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.4.8 Benelux PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.5.2 China PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.3 Japan PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.5 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.5.6 India PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.6.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.6.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa PD-1 and PD-L1 Immunotherapy Revenue, 2018-2030
6.7.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.3 Israel PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.4 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
6.7.5 UAE PD-1 and PD-L1 Immunotherapy Market Size, 2018-2030
7 PD-1 and PD-L1 Immunotherapy Companies Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Summary
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.1.5 AstraZeneca Key News & Latest Developments
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Company Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Key News & Latest Developments
7.3 F. Hoffmann-La Roche
7.3.1 F. Hoffmann-La Roche Company Summary
7.3.2 F. Hoffmann-La Roche Business Overview
7.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.3.5 F. Hoffmann-La Roche Key News & Latest Developments
7.4 Merck
7.4.1 Merck Company Summary
7.4.2 Merck Business Overview
7.4.3 Merck PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.4.5 Merck Key News & Latest Developments
7.5 Pfizer
7.5.1 Pfizer Company Summary
7.5.2 Pfizer Business Overview
7.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.5.5 Pfizer Key News & Latest Developments
7.6 Roche
7.6.1 Roche Company Summary
7.6.2 Roche Business Overview
7.6.3 Roche PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.6.5 Roche Key News & Latest Developments
7.7 Novartis
7.7.1 Novartis Company Summary
7.7.2 Novartis Business Overview
7.7.3 Novartis PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.7.5 Novartis Key News & Latest Developments
7.8 Jiangsu HengRui Medicine
7.8.1 Jiangsu HengRui Medicine Company Summary
7.8.2 Jiangsu HengRui Medicine Business Overview
7.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.8.5 Jiangsu HengRui Medicine Key News & Latest Developments
7.9 Innovent
7.9.1 Innovent Company Summary
7.9.2 Innovent Business Overview
7.9.3 Innovent PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.9.5 Innovent Key News & Latest Developments
7.10 Eli Lilly
7.10.1 Eli Lilly Company Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.10.5 Eli Lilly Key News & Latest Developments
7.11 GlaxoSmithKline
7.11.1 GlaxoSmithKline Company Summary
7.11.2 GlaxoSmithKline Business Overview
7.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Major Product Offerings
7.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue in Global Market (2018-2023)
7.11.5 GlaxoSmithKline Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
